seattle genetics inc (SGEN:NASDAQ GS)
As of 8:10 PM 06/19/13 All times are local (Market data is delayed by at least 15 minutes).
Financial Statements for seattle genetics inc (SGEN)
Year over year, Seattle Genetics Inc. has been able to grow revenues from $94.8M USD to $210.8M USD. Most impressively, the company has been able to reduce the percentage of sales devoted to cost of goods sold from 175.69% to 87.17%. This was a driver that led to an improvement in the bottom line from a loss of $152.0M USD to a smaller loss of $53.8M USD.
| Currency in Millions of US Dollars | As of: | Dec 31 2009 Restated | Dec 31 2010 Restated | Dec 31 2011 | Dec 31 2012 | 4 Year Trend |
| Revenues | 52.0 | 107.5 | 94.8 | 210.8 |  | |
| TOTAL REVENUES | 52.0 | 107.5 | 94.8 | 210.8 | | |
| Cost of Goods Sold | 119.1 | 146.4 | 166.5 | 183.8 | | |
| GROSS PROFIT | -67.2 | -38.9 | -71.7 | 27.0 | | |
| Selling General & Admin Expenses, Total | 17.7 | 29.3 | 72.7 | 84.3 | | |
| OTHER OPERATING EXPENSES, TOTAL | 17.7 | 29.3 | 72.7 | 84.3 | | |
| OPERATING INCOME | -84.9 | -68.2 | -144.4 | -57.3 | | |
| Interest and Investment Income | 3.2 | 1.9 | 1.1 | 3.5 | | |
| NET INTEREST EXPENSE | 3.2 | 1.9 | 1.1 | 3.5 | | |
| EBT, EXCLUDING UNUSUAL ITEMS | -81.7 | -66.3 | -143.3 | -53.8 | | |
| Gain (Loss) on Sale of Investments | -- | -- | -8.7 | -- | | |
| EBT, INCLUDING UNUSUAL ITEMS | -81.7 | -66.3 | -152.0 | -53.8 | | |
| Earnings from Continuing Operations | -81.7 | -66.3 | -152.0 | -53.8 | | |
| NET INCOME | -81.7 | -66.3 | -152.0 | -53.8 | | |
| NET INCOME TO COMMON INCLUDING EXTRA ITEMS | -81.7 | -66.3 | -152.0 | -53.8 | | |
| NET INCOME TO COMMON EXCLUDING EXTRA ITEMS | -81.7 | -66.3 | -152.0 | -53.8 | | |
| Recently Viewed | |||
| SGEN:US | $31.49 USD | -0.71 |  |
| Company | Last | Change |
| Cell Therapeutics Inc | $1.24 USD | -0.09 |
| Emergent Biosolutions Inc | $14.47 USD | -0.52 |
| Genmab A/S | kr181.80 DKK | -2.30 |
| ImmunoGen Inc | $15.96 USD | -0.42 |
| Immunomedics Inc | $4.43 USD | +0.13 |
| View Industry Companies | ||
Industry Analysis
SGEN
Industry Average
| Valuation | SGEN | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 17.6x |
|
| Price/Book | 16.7x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 16.2x |
|
Post a JobJobs
- Bothell, WA | Seattle GeneticsPosted: Jun 01
- Bothell, WA | Seattle GeneticsPosted: Jun 19
- Bothell, WA | Seattle GeneticsPosted: Jun 18
- Bothell, WA | Seattle GeneticsPosted: Jun 11
